Department of Cancer Medicine/Gynecology, Gustave Roussy, 114 rue Edouard Vaillant, 94800, Villejuif, France.
Departement of Laboratory Medicine and Pathology, Gustave Roussy, Villejuif, France.
Breast Cancer Res Treat. 2021 Jul;188(2):501-509. doi: 10.1007/s10549-021-06226-3. Epub 2021 Apr 23.
Women with breast cancer (BC) often suffer from severe vulvovaginal atrophy (VVA) which ultimately leads to poor sexual and urinary quality of life. We conducted a prospective study among women with BC and VVA, in order to evaluate the long-term effect of laser therapy on VVA.
Women with BC and VVA were proposed to have fractional microablative CO laser therapy (MonaLisaTouch®, DEKA) once per month for 3 months. Efficacy of laser therapy was assessed at baseline, 6 months and 18 months after treatment, using Female Sexual Function Index (FSFI) score, Ditrovie score and vaginal pH. A pap smear was also performed and the epithelial maturation pattern was noted. Paired statistical tests were used to compare results between baseline, 6 months and 18 months.
46 women with BC (median age [interquartile range] 56.5 years [47.0 - 59.4]) were included between May and October 2018. PH level slightly decreased over time (mean Δ at 18 months -0.3, SD = 0.7, p = 0.02) whereas maturation pattern on pap smear did not change. Sexual quality of life was significantly improved at 6 months and 18 months (mean Δ at 6 months 8.3, SD = 6.2 (p < 0.0001) and mean Δ at 18 months 4.3, SD = 8.4 (p = 0.01)). Ditrovie total score improved at 6 months (mean Δ -1.2, SD = 2.7, p = 0.01) but returned to baseline afterwards. Side effects were very mild. Three women developed low (2)- and high (1)-grade HPV-linked cervical lesions during follow-up.
Among women with BC, fractional microablative CO laser is effective on the long term on VVA symptoms and gynaecological quality of life.
ID-RCB 2018-A01500-55.
患有乳腺癌（BC）的女性常患有严重的阴道萎缩（VVA），这最终导致较差的性和尿失禁生活质量。我们对患有 BC 和 VVA 的女性进行了一项前瞻性研究，以评估激光治疗对 VVA 的长期效果。
建议患有 BC 和 VVA 的女性每月接受一次分数微剥脱 CO2 激光治疗（MonaLisaTouch®，DEKA），共 3 个月。在治疗后基线、6 个月和 18 个月，使用女性性功能指数（FSFI）评分、Ditrovie 评分和阴道 pH 值评估激光治疗的效果。还进行了巴氏涂片检查，并注意上皮成熟模式。使用配对统计检验比较基线、6 个月和 18 个月之间的结果。
2018 年 5 月至 10 月期间，纳入了 46 名患有 BC（中位数年龄[四分位数范围]56.5 岁[47.0-59.4]）的女性。pH 值随时间略有下降（18 个月时平均Δ-0.3，标准差=0.7，p=0.02），而巴氏涂片的成熟模式没有改变。性健康状况在 6 个月和 18 个月时显著改善（6 个月时平均Δ 8.3，标准差=6.2（p<0.0001），18 个月时平均Δ 4.3，标准差=8.4（p=0.01））。Ditrovie 总评分在 6 个月时改善（平均Δ-1.2，标准差=2.7，p=0.01），但随后恢复到基线。副作用非常轻微。在随访期间，有 3 名女性出现低（2）-和高（1）-级 HPV 相关宫颈病变。
在患有 BC 的女性中，分数微剥脱 CO2 激光治疗对 VVA 症状和妇科生活质量具有长期疗效。
ID-RCB 2018-A01500-55。
